Skip to main content

Table 1 Basic characteristics of the study population (n = 775)

From: No relationship between circulating levels of sex steroids and mammographic breast density: the Prospect-EPIC cohort

Age (years)

60.2 (5.4)

Height (cm)

163.7 (6.1)

Weight (kg)

69.7 (11.7)

Body mass index (kg/m2)

26.0 (4.1)

Waist–hip ratio

0.79 (0.06)

Family history of breast cancer (mother and/or sister with history of breast cancer)

106 (13.7)a

Reproductive factors

 

   Age at menarche (years)

13.5 (1.7)

   Nulliparous

99 (12.8)a

   Age at first child birth(years) (among parous women only)

25.4 (4.0)

   Number of children (average) (among parous women only)

2.6 (0.9)

   Ever breast feeding(among parous women only)

558 (82.5)a

   Age at menopause (years)

48.8 (4.9)

   Time since menopause (years)

11.2 (6.8)

Lifestyle factors

 

   Ever used oral contraceptives

416 (53.7)a

   Ever used hormone therapy

112 (14.4)a

   Time since stopped hormone therapy use (years) (among former hormone therapy users only)

7.1 (6.4)

   Current smoking

171 (22.1)a

   Ever smoked

421 (54.3)a

   Alcohol intake (g/day)

8.1 (11.2)

Sex steroids and sex hormone binding globulin

 

   Oestrone (pg/ml)

15.26 (4.38–53.16)b

   Oestradiol (pg/ml)

8.22 (2.92–23.17)b

   Free oestradiol (pg/ml)

0.24 (0.09–0.73)b

   Dehydroepiandrosterone sulfate (ng/ml)

446.7 (102.3–1,949.8)b

   Androstenedione (ng/ml)

0.46 (0.10–2.11)b

   Testosterone (ng/ml)

0.25 (0.09–0.72)b

   Free testosterone (pg/ml)

5.30 (1.46–19.23)b

   Sex hormone binding globulin (nmol/l)

19.63 (5.21–73.96)b

Breast measures

 

   Percentage breast density

21.7 (14.9–30.8)c

   Dense area

25.3 (18.4–35.5)c

   Nondense area

95.1 (70.1–121.9)c

  1. Data presented as the mean (standard deviation), unless stated otherwise: a n (%), bgeometric mean (± 2 standard deviations), cmedian (interquartile range).